RegenLab USA, a Switzerland-founded regenerative medicine company specializing in point-of-care cell-processing devices, has filed an S-1 with the SEC for an IPO. The Jersey City-based company plans to list on Nasdaq under “RGNA,” with StoneX Financial as sole bookrunner.
Founded by Chairman and CEO Antonino Turzi, who controls 98.64% of voting power, RegenLab operates R&D and manufacturing facilities in New Jersey, France and Switzerland.
Product sales rose 21% year over year to $29.32 million in the six months ended June 30, 2026, generating $2.10 million in operating income and $71,000 in net income versus losses a year earlier. Full-year 2025 revenue reached $49.17 million, while higher R&D spending resulted in a $1.24 million net loss.
RegenKit PRP and Cellular Matrix accounted for about 62% and 28.7% of 2025 product sales, respectively, with partnerships including Stryker, Smith+Nephew and MiMedx.
$NASDAQ